Live Breaking News & Updates on Maggie beller

Stay informed with the latest breaking news from Maggie beller on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Maggie beller and stay connected to the pulse of your community

Sutro Biopharma Appoints Jane Chung as Chief Commercial Officer

Sutro Biopharma Appoints Jane Chung as Chief Commercial Officer
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Germany , New-york , United-states , Columbia-university , South-san-francisco , California , San-francisco , Sutro-biopharma , Maggie-beller , Anniej-chang , Astrazeneca-us-immuno , Jane-chung

Sutro Biopharma Reports Second Quarter 2021 Financial Results, Business Highlights and Anticipated Second Half 2021 Milestones

Sutro Biopharma Reports Second Quarter 2021 Financial Results, Business Highlights and Anticipated Second Half 2021 Milestones
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Germany , New-york , United-states , California , San-diego , Columbia-university , South-san-francisco , Spain , American , Stanleyr-frankel , Maggie-beller , Sutro-xpress

Pharvaris Presents Clinical Data on Oral PHA121 Supporting the Prophylactic Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021

Share:
ZUG, Switzerland, July 10, 2021 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced the presentation of clinical data supporting the multiple-dose safety and pharmacokinetic (PK) profile of PHA121 (PHA-022121) for the treatment of hereditary angioedema (HAE) at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2021, being held virtually from July 10-16, 2021.
The double-blind, randomized, placebo-controlled, multiple ascending dose study included 38 male and female healthy volunteers. PHA121 was orally administered after standardized meals twice daily (BID) for 10 days in four sequential dosing cohorts, ranging from 12 to 50 mg, with safety and PK assessments during treatment and follow-up for 72 hours after the last dose. PHA121 was well-tolerated up to the highest dose of 50 mg BID. All reported treatment-emergent adverse events (TEAEs) were mild in intensity and resolved completely. The total incidence and type of AEs was comparable between active and placebo groups.

Switzerland , United-states , Peng-lu , Berndt-modig , Maggie-beller , Sarah-mccabe , Exchange-commission , Stern-investor-relations-inc , European-union , Russo-partners , European-academy-of-allergy , European-academy

Immunexpress Presents Data Supporting SeptiCyte® RAPID for COVID-19 Patient Triage as a Late-Breaking Abstract at ECCMID 2021

Immunexpress Presents Data Supporting SeptiCyte® RAPID for COVID-19 Patient Triage as a Late-Breaking Abstract at ECCMID 2021
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Spain , Barcelona , Comunidad-autonoma-de-cataluna , Maggie-beller , Rollandd-carlson , Roy-davis , European-congress , Russo-partners , Immunexpress-inc , Clinical-microbiology , Infectious-diseases , Hospital-del-mar

Sutro Biopharma to Participate in Two Virtual Investor Conferences in June

Sutro Biopharma to Participate in Two Virtual Investor Conferences in June
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Sutro-biopharma , Maggie-beller , Anniej-chang , Sutro-xpress , Raymond-james-human-health-innovations-conference , Celgene-corporation , Securities-life-sciences-conference , Nasdaq , Panel-session , Merck-kga , Sutro-biopharma-inc , Merck-kgaa

Puma Biotechnology Presents Data from the EGFR Exon 18-mutant NSCLC Cohort of the Phase II SUMMIT Trial at the 2021 ASCO Annual Meeting

Puma Biotechnology Presents Data from the EGFR Exon 18-mutant NSCLC Cohort of the Phase II SUMMIT Trial at the 2021 ASCO Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states , Maggie-beller , Jonathanw-goldman , Alanh-auerbach , Exchange-commission , Puma-biotechnology-inc , European-commission , Drug-administration , Drug-development , Nasdaq , Lung-cancer , Non-small-cell-metastatic-poster-session

Sutro Biopharma Earns Milestone Payment from Bispecific Antibody-Drug Conjugate Collaboration with Merck KGaA, Darmstadt, Germany

/PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), clinical-stage drug discovery, development and manufacturing company focused on the application of...

Germany , Sutro-biopharma , Trevor-hallam , Maggie-beller , Anniej-chang , Sutro-xpress , Celgene-corporation , Nasdaq , Exchange-commission , Prnewswire-sutro-biopharma-inc , Merck-kga , Sutro-biopharma-inc

Sutro Biopharma Announces Additional Data for Dose-Escalation Phase 1 Study of STRO-002 to be Presented at ASCO 2021

Share this article
Share this article
SOUTH SAN FRANCISCO, Calif., May 19, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced additional data from the Company's dose-escalation cohort of the Phase 1 study of STRO-002, a folate receptor alpha (FolRα) targeting antibody-drug conjugate (ADC) for patients with advanced, progressive ovarian cancer; the data will also be presented as a poster at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting to be held on June 4-8, 2021.

United-states , American , Sutro-biopharma , Maggie-beller , Anniej-chang , Arturo-molina , R-wendel-naumann , Sutro-xpress , American-society-of-clinical-oncology , Celgene-corporation , Company-corporate-presentation , Atrium-health

Sutro Biopharma Reports First Quarter 2021 Financial Results, Business Highlights and 2021 Anticipated Milestones

Sutro Biopharma Reports First Quarter 2021 Financial Results, Business Highlights and 2021 Anticipated Milestones
- Additional follow-up data on STRO-002 from the Phase 1 dose-escalation will be presented at ASCO 2021; enrollment for the dose-expansion is ongoing
- Merck initiated IND-enabling toxicology studies for the first program under the cytokine derivatives collaboration resulting in a $15 million milestone payment earned in April 2021
- EMD Serono began a Phase 1 study for the bispecific MUC1-EGFR ADC, M1231, during the first quarter of 2021
- Financial position remains strong with cash, cash equivalents and marketable securities of $294.9 million as of March 31, 2021 and projected runway into the second half of 2023

United-states , Spain , Spanish , American , Sutro-biopharma , Maggie-beller , Anniej-chang , R-wendel-naumann , Bristol-myers-squibb , Sutro-xpress , American-society-of-clinical-oncology , Exchange-commission-on

Cartesian Therapeutics Wins Fourth NIH Grant for Clinical Trials of RNA Cell Therapies

/PRNewswire/ -- Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company pioneering RNA cell therapy in and beyond oncology, today...

Maggie-beller , Murat-kalayoglu , National-cancer-institute , Small-business-innovation-research , National-institutes-of-health , National-institute-of-allergy , Russo-partners , National-heart , Blood-institute , National-institutes , National-institute , Infectious-diseases